Skip to main content

HomeResearchEndoluten

CategoryLongevity
SafetyLow Risk
StatusResearch Only

Endoluten

pineal peptide bioregulator · pineal Khavinson peptide · pineal cytomax

CategoryLongevity
Half-life
Routeoral, subcutaneous
RiskLow Risk
Providers1 listed

About Endoluten

Pineal-targeted peptide complex that modulates melatonin synthesis pathways and circadian gene expression. May help restore age-related decline in pineal activity and improve circadian rhythm regulation.

A short peptide bioregulator derived from pineal gland tissue, developed by the Khavinson Institute. Studied for circadian rhythm restoration, melatonin pathway support, and longevity — addressing the age-related decline in pineal gland function.

Research Areas

circadian rhythm supportmelatonin pathwaysleep qualitylongevity

Regulatory & Evidence

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.

Regulatory Status

Availability Status
Research Only

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Safety Notes

Low Risk

Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.

Reported contraindications & considerations

Pregnant Or Nursing

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Where to Find Endoluten

1 provider

Frequently Asked Questions — Endoluten

A short peptide bioregulator derived from pineal gland tissue, developed by the Khavinson Institute. Studied for circadian rhythm restoration, melatonin pathway support, and longevity — addressing the age-related decline in pineal gland function.

circadian rhythm support, melatonin pathway, sleep quality, longevity, anti-aging.

1 provider in the directory currently offers Endoluten.

Newsletter

The Peptide Research Digest

New providers, emerging stacks, and research developments — weekly.

No spam. Unsubscribe anytime. Privacy policy.